Why Diagnostic Algorithms for Pediatric aHUS Are Vital
Early diagnosis and intervention are critical for children with
thrombotic microangiopathies (TMAs).
Pediatric aHUS frequently presents with thrombocytopenia, hemolytic
anemia, and organ dysfunction, with acute renal injury being
especially common. Delayed diagnosis can quickly lead to
irreversible kidney injury and neurological complications
1,3
Diagnostic algorithms enable a systematic clinical approach for
children.
Since tools like the PLASMIC score are only validated in adults,
pediatric assessment relies even more on careful interpretation of
clinical features and laboratory parameters—such as the presence of
schistocytes, elevated LDH, and a negative Coombs test.
2,4
How Pediatric aHUS Diagnostic Algorithms Help
Standardized care
ensures all relevant symptoms—including reduced urine output, edema, hypertension, CNS signs, and abnormal renal function—are considered at presentation.1
Rapid decision-making
is supported by a clear pathway, so clinicians can move quickly from suspicion to confirmation and provide early, effective treatment.2
Accurate differentiation
between aHUS and other TMAs is facilitated by structured early assessment and focused tests, guiding appropriate therapy and avoiding unnecessary delays.2,4
Protecting Children from Delayed Diagnosis
Since aHUS may mimic other causes of TMA, prompt recognition and management are essential to reduce morbidity and prevent permanent damage. Diagnostic algorithms help ensure that no symptom or result—such as hemolytic anemia, organ dysfunction, or laboratory abnormalities—is missed, even in challenging presentations.1,2
DOWNLOAD the diagnostic
algorithm Here:
Routine use of a validated aHUS diagnostic algorithm in children
with suspected
TMA leads to faster, more accurate diagnosis
and allows earlier treatment—helping
prevent serious
complications like renal and neurological injury.1
Make early diagnosis standard—apply the aHUS diagnostic algorithm
with every pediatric patient you suspect of TMA.
Timely action
saves lives and protects children’s future health.
- Azoulay E, Knoebl P, Garnacho-Montero J, Rusinova K, Galstian G, Eggimann P, Abroug F, Benoit D, von Bergwelt-Baildon M, Wendon J, Scully M. Expert statements on the standard of care in critically ill adult patients with atypical hemolytic uremic syndrome. Chest. 2017 Aug 1;152(2):424-34.
- Blasco M, Guillén-Olmos E, Diaz-Ricart M, Palomo M. Complement mediated endothelial damage in thrombotic microangiopathies. Frontiers in Medicine. 2022 Apr 25;9:811504.
- Raina R, Krishnappa V, Blaha T, Kann T, Hein W, Burke L, Bagga A. Atypical hemolytic uremic syndrome: an update on pathophysiology, diagnosis, and treatment. Therapeutic Apheresis and Dialysis. 2019 Feb;23(1):4-21.
- Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. InSeminars in nephrology 2013 Nov 1 (Vol. 33, No. 6, pp. 508-530). WB Saunders.
- Tseng MH, Lin SH, Tsai JD, Wu MS, Tsai IJ, Chen YC, Chang MC, Chou WC, Chiou YH, Huang CC. Atypical hemolytic uremic syndrome: Consensus of diagnosis and treatment in Taiwan. Journal of the Formosan Medical Association. 2023 May 1;122(5):366-75.
- McFarlane PA, Bitzan M, Broome C, Baran D, Garland J, Girard LP, Grewal K, Lapeyraque AL, Patriquin CJ, Pavenski K, Licht C. Making the correct diagnosis in thrombotic microangiopathy: a narrative review. Canadian Journal of Kidney Health and Disease. 2021 Apr;8:20543581211008707.
- Yerigeri K, Kadatane S, Mongan K, Boyer O, Burke LL, Sethi SK, Licht C, Raina R. Atypical Hemolytic-Uremic Syndrome: Genetic Basis, Clinical Manifestations, and a Multidisciplinary Approach to Management. Journal of Multidisciplinary Healthcare. 2023 Dec 31:2233-49.
- Hofer J, Rosales A, Fischer C, Giner T. Extra-renal manifestations of complement-mediated thrombotic microangiopathies. Frontiers in pediatrics. 2014 Sep 8;297.